ES2196031T3 - Derivados peptidicos terapeutico. - Google Patents

Derivados peptidicos terapeutico.

Info

Publication number
ES2196031T3
ES2196031T3 ES94924590T ES94924590T ES2196031T3 ES 2196031 T3 ES2196031 T3 ES 2196031T3 ES 94924590 T ES94924590 T ES 94924590T ES 94924590 T ES94924590 T ES 94924590T ES 2196031 T3 ES2196031 T3 ES 2196031T3
Authority
ES
Spain
Prior art keywords
peptide
therapeutic derivatives
derivatives
peptidic
peptidic therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924590T
Other languages
English (en)
Inventor
Sun Hyuk Kim
Zhengxin Dong
John E Taylor
Sylviane Moreau
Susan Riley Keyes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Application granted granted Critical
Publication of ES2196031T3 publication Critical patent/ES2196031T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE DESCRIBEN DERIVADOS PEPTIDICOS, QUE CONTIENEN UNO O MAS SUSTITUYENTES, UNIDOS CADA UNO POR UN ENLACE AMIDA, AMINO O SULFONAMIDA, A UN GRUPO AMINO, BIEN SOBRE EL EXTREMO N-TERMINAL O EN LA CADENA LATERAL DE UNA FRACCION PEPTIDICA BIOLOGICAMENTE ACTIVA. LOS DERIVADOS PEPTIDICOS, PRESENTAN UNA ACTIVIDAD BIOLOGICA INCREMENTADA, CUANDO SE LOS COMPARA CON EL CORRESPONDIENTE PEPTIDO POR SI SOLO.
ES94924590T 1993-08-09 1994-08-08 Derivados peptidicos terapeutico. Expired - Lifetime ES2196031T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10419493A 1993-08-09 1993-08-09

Publications (1)

Publication Number Publication Date
ES2196031T3 true ES2196031T3 (es) 2003-12-16

Family

ID=22299154

Family Applications (3)

Application Number Title Priority Date Filing Date
ES02026862T Expired - Lifetime ES2229045T3 (es) 1993-08-09 1994-08-08 Derivados de peptidos terapeuticos.
ES02026863T Expired - Lifetime ES2309131T3 (es) 1993-08-09 1994-08-08 Derivados peptidos terapeuticos.
ES94924590T Expired - Lifetime ES2196031T3 (es) 1993-08-09 1994-08-08 Derivados peptidicos terapeutico.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES02026862T Expired - Lifetime ES2229045T3 (es) 1993-08-09 1994-08-08 Derivados de peptidos terapeuticos.
ES02026863T Expired - Lifetime ES2309131T3 (es) 1993-08-09 1994-08-08 Derivados peptidos terapeuticos.

Country Status (30)

Country Link
US (1) US5552520A (es)
EP (3) EP1288224B1 (es)
JP (3) JP3618750B2 (es)
KR (1) KR100325972B1 (es)
CN (1) CN1055700C (es)
AT (3) ATE241643T1 (es)
AU (1) AU689490B2 (es)
CA (1) CA2168113C (es)
CZ (3) CZ292586B6 (es)
DE (3) DE69434181T2 (es)
DK (3) DK0788509T3 (es)
ES (3) ES2229045T3 (es)
FI (1) FI960584A (es)
GE (1) GEP20002146B (es)
HK (2) HK1053313A1 (es)
HU (1) HU224350B1 (es)
LT (1) LT4078B (es)
LV (1) LV11549B (es)
MD (1) MD1591B2 (es)
NZ (1) NZ271238A (es)
PL (1) PL180612B1 (es)
PT (2) PT1288223E (es)
RO (1) RO117259B1 (es)
RU (1) RU2133252C1 (es)
SG (1) SG75092A1 (es)
SI (2) SI0788509T1 (es)
SK (1) SK15096A3 (es)
UA (1) UA44707C2 (es)
WO (1) WO1995004752A1 (es)
ZA (1) ZA945966B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
CA2190633A1 (en) * 1995-03-20 1996-09-26 Kenji Shibata Novel calcitonin derivatives
US5824772A (en) * 1995-04-04 1998-10-20 Advanced Bioconcept, Inc. Fluorescent somatostatin
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US7078413B2 (en) 1996-04-19 2006-07-18 Wisconsin Alumni Research Foundation Compositions and methods of use for a bombesin peptide
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
PL352763A1 (en) * 1999-06-25 2003-09-08 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Somatostatin agonists
US6864234B1 (en) 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
AU2004200688B2 (en) * 1999-08-18 2007-01-25 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
JP4303438B2 (ja) * 1999-08-18 2009-07-29 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ペプチドの持続放出製剤
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
MD2074G2 (ro) * 2000-12-29 2003-06-30 Юрий НИКИТИН Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată
RU2352578C2 (ru) 2001-03-06 2009-04-20 Иль Консорцио Феррара Ричерке Способ модуляции пролиферации клеток медуллярной карциномы щитовидной железы
CZ299362B6 (cs) * 2001-03-08 2008-07-02 The Administrators Of The Tulane Educational Fund Antagonisté somatostatinu
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
FR2833596B1 (fr) * 2001-12-14 2005-02-18 Aventis Pharma Sa Procede de preparation de derives d'echinocandine
US20040171070A1 (en) * 2002-05-20 2004-09-02 Ramagauri Bhikhabhai Peptide analysis using a solid support
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
AU2009259034B2 (en) 2008-06-12 2013-10-31 Ipsen Bioinnovation Limited Suppression of cancers
EP2310028B1 (en) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20120172650A1 (en) * 2009-03-18 2012-07-05 Laurence Katznelson Use of somatostatin or an analogue thereof in combination with external radiation therapy
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA2782056C (en) 2009-11-25 2021-03-09 Arisgen Sa Mucosal delivery of peptides
US9352012B2 (en) 2010-01-13 2016-05-31 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
CN108659100A (zh) * 2017-03-28 2018-10-16 上海新生源医药集团有限公司 具有镇痛作用的多肽及其应用
AU2019357621A1 (en) 2018-10-11 2021-05-27 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
KR20220017695A (ko) * 2020-08-05 2022-02-14 주식회사 레미바이오 아스코르브산 유도체 및 이를 포함하는 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
GB2218102B (en) * 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
NO893088L (no) 1988-08-18 1990-02-19 Syntex Inc Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser.
BE1003762A3 (fr) 1988-11-11 1992-06-09 Sandoz Sa Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives.
DE69024230T2 (de) * 1989-12-22 1996-05-02 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives

Also Published As

Publication number Publication date
JPH09501177A (ja) 1997-02-04
PT788509E (pt) 2003-10-31
WO1995004752A1 (en) 1995-02-16
EP1288224B1 (en) 2008-06-25
EP0788509A1 (en) 1997-08-13
DK1288224T3 (da) 2008-10-13
JP3618750B2 (ja) 2005-02-09
DE69432758T2 (de) 2004-02-19
HU9600281D0 (en) 1996-04-29
LV11549B (en) 1997-04-20
DK1288223T3 (da) 2005-03-29
CZ39096A3 (en) 1996-11-13
CN1055700C (zh) 2000-08-23
KR100325972B1 (ko) 2002-07-27
RO117259B1 (ro) 2001-12-28
CA2168113A1 (en) 1995-02-16
ATE399177T1 (de) 2008-07-15
HK1053313A1 (en) 2003-10-17
DE69434181T2 (de) 2005-12-01
ES2229045T3 (es) 2005-04-16
JP2005015488A (ja) 2005-01-20
LV11549A (lv) 1996-10-20
SI0788509T1 (en) 2003-10-31
EP1288224A1 (en) 2003-03-05
CA2168113C (en) 2002-10-01
EP0788509B1 (en) 2003-05-28
CN1133047A (zh) 1996-10-09
LT4078B (en) 1996-12-27
MD960137A (en) 1999-01-31
FI960584A0 (fi) 1996-02-08
DE69434181D1 (de) 2005-01-13
UA44707C2 (uk) 2002-03-15
EP0788509A4 (en) 1999-07-14
PL312989A1 (en) 1996-05-27
RU2133252C1 (ru) 1999-07-20
SK15096A3 (en) 1996-07-03
DE69435105D1 (de) 2008-08-07
HU224350B1 (hu) 2005-08-29
ATE284413T1 (de) 2004-12-15
MD1591B2 (ro) 2001-01-31
PL180612B1 (pl) 2001-03-30
NZ271238A (en) 1997-10-24
HK1053314A1 (en) 2003-10-17
CZ292586B6 (cs) 2003-10-15
LT96025A (en) 1996-07-25
ZA945966B (en) 1995-06-26
PT1288223E (pt) 2005-03-31
JP3869439B2 (ja) 2007-01-17
SI9420051A (en) 1996-12-31
JP2004339237A (ja) 2004-12-02
US5552520A (en) 1996-09-03
CZ289552B6 (cs) 2002-02-13
EP1288223A1 (en) 2003-03-05
GEP20002146B (en) 2000-06-25
AU7481994A (en) 1995-02-28
DE69432758D1 (en) 2003-07-03
ATE241643T1 (de) 2003-06-15
DK0788509T3 (da) 2003-06-23
JP3785179B2 (ja) 2006-06-14
EP1288223B1 (en) 2004-12-08
ES2309131T3 (es) 2008-12-16
AU689490B2 (en) 1998-04-02
SG75092A1 (en) 2000-09-19
HUT73491A (en) 1996-08-28
CZ289590B6 (cs) 2002-02-13
FI960584A (fi) 1996-02-08

Similar Documents

Publication Publication Date Title
ES2196031T3 (es) Derivados peptidicos terapeutico.
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
DE69024965T2 (de) Dehydrodidemnin b
ES2192620T3 (es) Polipeptido receptor de il-13.
DE69613137D1 (de) Zyklische peptidanaloga von somatostatin
ATE278710T1 (de) Antimikrobiell wirksame peptide
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
ES2058479T3 (es) Compuestos peptidicos.
ATE90359T1 (de) Peptide.
DE3869939D1 (de) Biologisch wirksame peptide.